Alwin Schuller

Alwin Schuller

Company: AstraZeneca

Job title: Senior Principal Scientist


Alwin has ~20 years’ industry experience mentoring diverse research teams and providing biology and in vivo pharmacology strategy to various small molecule and antibody projects ranging from target validation through clinical development. The past ~7 years he has held various roles at AstraZeneca including bioscience lead of the Arginase program (from inception to candidate selection), the A2AR inhibitor AZD4635, and the MET inhibitor AZD6094 / savolitinib. 


Discussion/Q&A 2:25 pm

Read more

day: Day One

Anti Tumor Activity of the Novel Arginase Inhibitor AZD0011 in Syngeneic Tumor Models, & Tumor Genetics Shape the Immune Landscape in Humanized Mouse Models 1:30 pm

Developed a novel arginase inhibitor, AZD0011 that in vivo shows a time and dose dependent PK and PD and several signs of immune activation AZD0011 shows single agent anti-tumor activity in various syngeneic tumor models and can be combined with various therapies including checkpoint inhibitors Development of humanized mouse models show distinct immune subset engraftment…Read more

day: Day One

Roundtable Lunch 12:40 pm

• Do you use humanized/HuGEMM mice to investigate other aspects of your therapeutic besides efficacy? • At what stage of the drug development workflow should we start to investigate any potential irAE toxicity of immunotherapies? • What are your thoughts on using humanized/HuGEMM mice to investigate irAE? • What are some of the models used…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.